BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
Beijing-based biotechnology company, BeiGene, was granted approval by China’s National Medical Products Administration (NMPA) on April 15th to administer their novel anti-PD-1 antibody, tislelizumab, to patients with second-line esophageal squamous cell carcinoma (ESCC). ESCC is by far the world’s most pervasive esophageal cancer accounting for about 90% of roughly 456,000 recorded cases each year.
It's free! Log in now to read